Latigo Biotherapeutics at a glance
As of- [1] Lead investors: PR Newswire, February 14, 2024
- [2] Founded: BioXconomy (retrieved August 2026)
- [3] Headquarters: Pacific Coast Business Times (retrieved July 23, 2024)
What Latigo Biotherapeutics does
Latigo Biotherapeutics is a Thousand Oaks, California, clinical-stage biopharmaceutical company developing non-opioid pain medicines.[1] It was launched in 2018 as WVB-Desmond Inc. by Westlake Village BioPartners, a life sciences venture firm.[1] The company changed its name to Latigo Biotherapeutics in 2019.[1] Its lead product candidate, LTG-001, is an oral Nav1.8 inhibitor for acute pain.[2] The FDA granted LTG-001 Fast Track designation in March 2025.[1],[3] In July 2026 the New England Journal of Medicine published results from a 343-patient trial of LTG-001 in moderate-to-severe pain after abdominoplasty.[4],[2] The study met its primary endpoint, summed pain intensity difference over 48 hours versus placebo.[4] Gross proceeds were expected to be $345.6 million.[2] The shares began trading on August 7, 2026, under the ticker LTGO.[2]
Leadership
- Nima Farzan became chief executive in 2024.[1]
Is this your company? Get featured or correct your listing →
Company Snapshot
Latigo Biotherapeutics is a biotech company, based in Thousand Oaks, California, USA, founded 2018. Market cap ~$1.39B (Sept 2026) (As of Sep 2026, Value Add Pulse research). Total funding $321.5M (pre-IPO) (As of Aug 2026).
Recent changes
- Sep 2026Sep 2026First reported market cap: ~$1.39B (Sept 2026)Estimated Value Add Pulse enrichment
- Aug 7, 2026Aug 7, 2026Latigo Biotherapeutics Jumps 17% in $345.6M IPO Pulse story
- Aug 6, 2026Aug 6, 2026IPO $345.6M StockTitan
- Aug 2026Aug 2026First reported total funding: $321.5M (pre-IPO) BioXconomy
- Jan 2025Jan 2025Raised $150M Series B Value Add Pulse enrichment
Earlier changes (2)
- Feb 14, 2024Feb 14, 2024Raised $135M Series A PR Newswire
- Feb 14, 2024Feb 14, 2024New investor: Westlake Village BioPartners PR Newswire
Funding history
2 equity events · newest first · sources dated per row| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Jan 2025 | Series Bnot counted: no linked source | $150M | — | — | Value Add Pulse research |
| Feb 14, 2024 | Series A | $135M | — | Westlake Village BioPartnersunverified | PR Newswire |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Debt, IPO & other events
not counted in equity raised| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2026 | IPO | $345.6M | — | StockTitan |
Investors
Latest Pulse
- Aug 31, 2026Biotech Funding Held Its Ground While AI Took the OxygenGlobal biotech startup investment is tracking to its usual $36 billion to $40 billion range in 2026 despite the AI capital surge, with more than $6 billion of that going to AI-native drug discovery companies.→
- Aug 10, 2026Biotech IPO Window Closes Its Strongest Week Since SpringBlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.→
- Aug 10, 2026Attovia Therapeutics Climbs 29% After $289M IPOAttovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.→
- Aug 7, 2026Latigo Biotherapeutics Jumps 17% in $345.6M IPOLatigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.→
- Aug 5, 2026Goldman-Backed Attovia Prices IPO, Lists on NasdaqAttovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.→
- Aug 5, 2026Attovia Prices $289M Nasdaq IPO at $17 a ShareAttovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.→
- Aug 4, 2026Attovia Prices IPO as Biotech's Public Pipeline Fills OutAttovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.→
- Aug 4, 2026Latigo Sets Terms for a $272M Nasdaq IPOLatigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.→
- Aug 3, 2026BlossomHill Files for $100M Nasdaq IPO in Cancer DrugsBlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.→
- Aug 3, 2026Blue Owl-Backed Latigo Advances Nasdaq IPO PlansLatigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.→
Coverage Timeline
newest first- Aug 10, 2026IPOBiotech IPO Window Closes Its Strongest Week Since Spring~$972M, 4 deals→
- Aug 7, 2026IPOLatigo Biotherapeutics Jumps 17% in $345.6M IPO$345.6M IPO→
- Aug 4, 2026IPOAttovia Prices IPO as Biotech's Public Pipeline Fills Out$17/share IPO→
- Aug 4, 2026IPOLatigo Sets Terms for a $272M Nasdaq IPO$272M IPO→
- Aug 3, 2026IPOBlue Owl-Backed Latigo Advances Nasdaq IPO Plans→
All Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
Latigo Biotherapeutics Jumps 17% in $345.6M IPO
IPO$345.6M IPO
Latigo Biotherapeutics Jumps 17% in $345.6M IPO
Latigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.
FOLLOW-UP
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
Latigo Sets Terms for a $272M Nasdaq IPO
IPO$272M IPO
Latigo Sets Terms for a $272M Nasdaq IPO
Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
IPO
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.
Value Add Research
Related Companies
Shared investors
Latigo Biotherapeutics FAQ
Who invested in Latigo Biotherapeutics?
In March 2025 it closed a $150 million Series B led by funds managed by Blue Owl Capital.[3]
What does Latigo Biotherapeutics do?
Latigo Biotherapeutics is a Thousand Oaks, California, clinical-stage biopharmaceutical company developing non-opioid pain medicines.[1]
When was Latigo Biotherapeutics founded and where is it based?
Latigo Biotherapeutics was founded in 2018 and is headquartered in Thousand Oaks, California, USA, according to BioXconomy and Pacific Coast Business Times.
References
researched 2026-10-24Sources & methodologyshow
Where these figures come from
- PR Newswireprimary source1 fact
- StockTitanresearch database1 fact
- Value Add Pulse researchValue Add VC data2 facts
- BioXconomyValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.